You are about to leave www.astellas.com and enter a third-party website. Astellas is not responsible for the content or services on the third-party website.
Would you like to continue?
Enabling health with integrity and innovation
With the deep understanding of patient needs, we design our products and process across various modalities. We define VALUE from our manufacturing and supply throughout product lifecycle across five dimensions:
Astellas is committed to continuously investing in advanced facilities to ensure a reliable supply of our products with quality. By developing state-of-the-art in-house capabilities and partnering with external organizations, we are building a more robust manufacturing network that enables us to deliver our products to the patients who need them most.
Japan
Ireland
United States
China
We are dedicated to providing supplies that consistently meet the standards of quality and timelines. Reliable supply with quality starts with robust process design and effective knowledge transfer to both our internal and external manufacturing partners. This commitment is supported by an efficient and agile end-to-end supply chain. Moreover, we foster a culture of continuous improvement and quality, which is essential for meeting the needs of patients and healthcare professionals.
CTM, Commercial
The Yaizu Technology Center is Astellas' largest manufacturing site for pharmaceutical formulations. It produces both oral and sterile formulations, serving commercial production and clinical trial material (CTM). The facility is committed to global GMP standards and ensures consistent, high-quality output.
It is co-located with the CMC* laboratories, which conduct research and development activities aimed at maintaining and advancing cutting-edge manufacturing technologies.
*Chemical Manufacturing and Control: a series of processes related to the development, manufacturing, and quality control of pharmaceuticals
CTM, Commercial
The Toyama Technology Center in Toyama, known as the "City of Medicine," has a footprint of 191,000 square meters. Beginning operations in 1992, it specializes in the commercial production of antibody products and fermentation-derived low molecule product, using the latest biotechnology, and offers comprehensive production capabilities for drug substance (DS), formulation and packaging.
The facility and its quality system comply with global GMP standards, and the facility has the capability to manufacture active pharmaceutical ingredients (APIs), intermediates, and packaging processes. Digital applications are utilized for effective manufacturing and quality control, delivering safe and reliable medicines to patients.
CTM, Commercial
The Takahagi Technology Center is Astellas' largest manufacturing site for chemical synthetic drug substances (DS) and chemical components of bio products, both commercial products and clinical trial materials (CTM).
It upholds high quality in accordance with GMP standards focusing on safety and environmental considerations.
The facility also contributes to manufacturing and analytical process development and improvement collaborating with CMC* laboratories to ensure a reliable supply.
*Chemical Manufacturing and Control: a series of processes related to the development, manufacturing, and quality control of pharmaceuticals
CTM
The Tsukuba Tokodai Technology Center in Tsukuba, Ibaraki, specializes in manufacturing developmental biopharmaceutical drug substances (DS) and clinical trial materials (CTM).
The facility operates under a quality system that complies with GMP standards, ensuring the highest level of quality and safety. Along with co-located CMC* laboratories, they utilize cutting-edge biotechnology to manufacture innovative therapies, contributing to advancements in medical treatment.
The team’s commitment to excellence enables them to deliver high-quality products that significantly impact patients' lives.
*Chemical Manufacturing and Control: a series of processes related to the development, manufacturing, and quality control of pharmaceuticals
Commercial
The Kerry Plant is a pharmaceutical facility established in Killorglin, County Kerry in 1990, and currently employs 400 employees and up to 80 contractors. It is involved in the manufacturing of pharmaceutical products, focusing on the production of lifesaving medications with a strong emphasis on sustainability and environmental stewardship.
The plant formulates Prograf, Astellas’ important and innovative immunosuppressant drug, which is used to prevent the rejection of transplanted organs. It utilizes the latest encapsulation, ampoule filling and packaging technology, with worldwide distribution managed by the facility.
Commercial
The Dublin Plant is a manufacturing campus for active pharmaceutical ingredients (APIs) used in medicinal products, established in 1986. Located in West Dublin, the site offers convenient access to Dublin Airport, the city center, and several of Ireland’s leading universities.
Astellas currently utilizes approximately one-third of the 50-acre (202,300-square-meter) site for production and related activities, with the remaining land reserved for future development and expansion. The site currently employs 120 employees and up to 80 contract personnel.
The bulk APIs produced at the site include Mirabegron, Solifenacin, and Tamsulosin—used in the treatment of overactive bladder and prostate gland disorders. These products are shipped to customers for final formulation, packaging, and global distribution. The site operates with a strong emphasis on operational excellence, sustainability, and environmental stewardship.
Commercial
The Tralee Plant is a bio-pharmaceutical fill-finish facility under construction and commissioning, and the first commercial production is expected in early 2028. It will create 120 full-time roles along with contractors and outsourced services, making it a key employer in Tralee and County Kerry.
The plant will produce parenteral products, and biologics such as monoclonal antibodies (mAbs) and antibody drug conjugates (ADCs) using cutting-edge compounding, sterile aseptic filling and lyophilization manufacturing technologies. Advanced laboratory analysis and testing helps to ensure products are produced safely and with the desired intended result for patients.
Designed to high energy standards, the plant incorporates sustainability features such as solar photovoltaic panels, a biomass boiler, high-performance building envelope, high-efficiency heat pumps, electric vehicle charging stations, and magnetic levitating process chillers for superior efficiency at part-load conditions.
CTM, Commercial
The Sanford Technology Center in Sanford, North Carolina, is designed to support suspension-based cell culture and downstream purification of drug substance (DS) operations. Drug product capabilities are currently being installed and expected to be GMP ready in FY2026. Sanford specializes in gene therapy production with the potential to support other modalities.
The 134,000-square-foot (approximately 12,500-square-meter) facility includes over 19,000 square feet (approximately 1,800 square meters) of process cleanroom and QC laboratory spaces. GMP clinical trial operations were first executed in 2023. The facility utilizes innovative biotechnology equipment, validated cleanrooms, and quality systems required to support complex gene therapy operations. The facility is also equipped with state-of-the-art analytical equipment used to perform qualified assays required to test and release AAV products.
The Sanford team’s commitment to process excellence, quality assurance, and reliability enables them to deliver valuable solutions poised to positively impact patients' lives around the world.
CTM, Commercial
The Massachusetts Technology Center (MA-TC) in Westborough, Massachusetts is a facility that specializes in the production of regenerative cellular therapeutics for clinical trials.
The MA-TC GMP facility has a total footprint of over 44,000 square feet (approximately 4,100 square meters), featuring highly controlled clean room environment consistently monitored and maintained per approved procedures. The clean rooms operated under the quality management system comply with GMP standards for aseptic processing, ensuring the highest quality and safety of the drug products produced for clinical use.
The site has integrated digital solutions to further enhance the quality and compliance under which products are manufactured. All products produced in their clean rooms enable them to deliver innovative therapies that significantly and positively impact and improve patients' lives.
Commercial
The Shenyang Plant is a key manufacturing site for Astellas in China. It is equipped with functions for encapsulating, inspection, packaging, warehousing, and distributing.
The facility manufactures and distributes products in accordance with GMP/ISO for the Chinese market ensuring high quality and meeting the needs of the local community.
As part of Astellas' global manufacturing network, the Shenyang Plant plays an important role in delivering reliable products to patients.
